Procos was founded in 1945 by two entrepreneurial chemists. Their “think globally, act locally” approach remains a key factor to successfully internationalize a company deep-rooted in the north Italian village of Cameri, on the outskirts of Novara. Nowadays Procos is a worldwide-recognized supplier of Active Ingredients, intermediates and related services for the pharmaceutical industry.

For over seventy years of activity, Procos has been sustaining its constant contribution to the local economy with a considerable investment in people, know-how and technology. Since being acquired in 2006 by the Japanese group CBC Co. Ltd, Procos started enlarging its virtual borders with the establishment of liaison offices in USA, Slovakia, Germany and India.

Our mission is to increase our market share, with mutual prosperity and satisfaction of our customers, stockholders and employees.
**HUMAN TOUCH**

People are Procos’ asset: we apply a “melting pot” philosophy, where our employees bring a vast diversity of experience and education. We emphasize intangibles and strive to let our customers benefit from the added value we deliver together with our service. Reliability, effectiveness, timeliness, efficiency, confidentiality: is there any need to rank the values we offer?

**GOING FORWARD**

We minimize environmental impact and energy consumption by optimizing processes and applying new technologies. The ISO 14001 and OHSAS 18001 certifications are a concrete sign of our attention to environment and safety.

Our manufacturing site, which is over 100,000 m², has been going through a robust investment program: the first round of investments involved the setup of a cGMP Kilolab, a deep revamping of the finishing RP department and the enlargement of the QC and R&D laboratories.

A second wave of investments enabled us to set up a cGMP Minilab, for High Potency APIs production, and a new Multipurpose Unit which increased our production capacity to 450m³.

A further 2-years investment currently in progress, covers the addition of a new Small Scale cGMP production Unit and a High Potency Cytotoxic APIs production Unit including R&D and QC laboratories.
EXPERIENCE AND INNOVATION

Custom synthesis and generic APIs have been our two business sectors from the beginning. Our R&D team consists of a qualified and skilled group of researchers (PhD and technicians) dedicated to the development (innovation and optimization) and scaling up of the chemical processes. We apply up-to-date techniques when designing innovative synthetic processes or optimizing existing ones (based upon the customer’s technical package), with the constant aim of fast, safe and effective results.

COMPLIANCE

Procos is authorized by AIFA (Italian Health Authority) to produce human and veterinary Active Pharmaceutical Ingredients, both for commercial and for clinical supply purposes. Our state of the art facility is designed under full cGMP compliance and follows a strict quality management policy. Our compliance with the most updated regulatory guidelines is routinely verified through on-site inspections both by customers and by main foreign regulatory bodies, such the U.S. FDA and the Japanese PMDA.
DREAM TOGETHER

Founded in Tokyo in 1925 as a trading company specialized in chemicals, CBC was restructured during the 1970s to globalize the business and venture into manufacturing. Entering the 21st century, CBC accelerated the expansion of overseas production and sales offices, becoming a “monozukury (literally: making things) trading company,” through:

CBC Co., Ltd., active in the production of optical information processing equipment,
CBC INGS COMPANY, dealing with production of electronic device materials,
PROCOS SpA, producing APIs and their intermediates
CBC FORMA, taking care of development support, thus design and production of prototypes and parts.

“A dream you dream alone is only a dream. A dream you dream together is reality.”
J. Lennon